Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One scan to catch two silent threats: MRI may spot bone and muscle loss in kidney patients

NCT ID NCT07645794

Diagnosis Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a single MRI fat-fraction (MRI-FF) scan can accurately diagnose osteoporosis and sarcopenia (muscle loss) in people with chronic kidney disease (CKD). Researchers will compare MRI-FF results with standard DXA scans in 868 participants—half with CKD and half without. If proven reliable, MRI-FF could offer a faster, radiation-free way to detect these common complications early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI fat-fraction (MRI-FF) scan
What this could lead to
If successful, this could provide a single, non-invasive scan to detect both osteoporosis and sarcopenia early in CKD patients, improving diagnosis without radiation.
What could go wrong
This is an observational study, not a treatment trial. The MRI-FF method may not prove accurate enough to replace current standards like DXA, and results may not apply to all CKD stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 868 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of two groups: 434 patients with chronic kidney disease (CKD) and 434 age- and sex-matched healthy controls without CKD. All participants are adults aged 18-80 years old who are able to complete the required MRI scans.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 80 years old. 2. Able to understand and sign the informed consent form. 3. Able to complete MRI-FF scans of the lumbar spine and thigh. 4. For CKD group: Confirmed diagnosis of chronic kidney disease (eGFR \< 60 mL/min/1.73m² for ≥3 months). 5. For control group: No history of chronic kidney disease and normal renal function. Exclusion Criteria: 1. Contraindications to MRI (e.g., pacemaker, metal implants, severe claustrophobia). 2. History of primary bone metabolic disorders (e.g., osteoporosis, hyperparathyroidism) unrelated to CKD. 3. Current use of anti-osteoporotic drugs (e.g., bisphosphonates, teriparatide). 4. Severe lower limb deformity or amputation affecting thigh muscle assessment. 5. Inability to cooperate with the scan due to cognitive impairment or severe illness.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome osteoporosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease Osteoporosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.